Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance
March 17-20, 2024 | Fairmont Chateau Whistler, Whistler, BC, Canada
Scientific Organizers:
James P. Allison, Andrea Schietinger, Antoni Ribas and Padmanee Sharma
In Person
On Demand
March 17-20, 2024 | Fairmont Chateau Whistler, Whistler, BC, Canada
Scientific Organizers:
James P. Allison, Andrea Schietinger, Antoni Ribas and Padmanee Sharma
Available Formats:
In Person
On Demand
Supported by the Directors' Fund
Available Formats: = In Person = On Demand
Registration
4:00–8:00 PM
Macdonald Foyer
Welcome Mixer
6:00–8:00 PM
Macdonald Foyer
Breakfast
7:00–8:00 AM
MacDonald CDEF
Welcome and Keynote Address
8:00–9:00 AM
Macdonald AB
James P. Allison, University of Texas MD Anderson Cancer Center
Immune Checkpoint Blockade in Cancer Therapy: New Insights into Therapeutic Mechanisms of anti-CTLA4 and anti-PD-1
Immune Checkpoint Blockade in Cancer Therapy: New Insights into Therapeutic Mechanisms of anti-CTLA4 and anti-PD-1
Clinical Trials to Identify Mechanisms of Response and Resistance
9:00–11:15 AM
Macdonald AB
Andrea Cercek, Memorial Sloan Kettering Cancer Center
Single Agent PD-1 Blockade as Curative-Intent Treatment in Mismatch Repair Deficient Locally Advanced Rectal Cancer
Single Agent PD-1 Blockade as Curative-Intent Treatment in Mismatch Repair Deficient Locally Advanced Rectal Cancer
Coffee Break
9:30–9:50 AM
Macdonald Foyer
On Own for Lunch
11:15–5:00 PM
Poster Setup
11:15–1:00 PM
MacDonald CDEF
Poster Viewing
1:00–10:00 PM
MacDonald CDEF
Panel Discussion on Failed Trials
2:30–4:30 PM
Macdonald AB
Antoni Ribas, University of California, Los Angeles
Role of IFN-gamma in Response and Resistance to Cancer Immunotherapies
Role of IFN-gamma in Response and Resistance to Cancer Immunotherapies
Padmanee Sharma, University of Texas MD Anderson Cancer Center
Neoadjuvant and Tissue-based Trials for Evaluating Mechanisms of Response and Resistance
Neoadjuvant and Tissue-based Trials for Evaluating Mechanisms of Response and Resistance
Georgina V. Long, Melanoma Institute Australia, The University of Sydney
Neoadjuvant Therapy: Where We Have Come from and Where to Next
Neoadjuvant Therapy: Where We Have Come from and Where to Next
Coffee Available
4:30–5:00 PM
Macdonald Foyer
Regulation of Immune Responses by Myeloid Cells, Dendritic Cells and Tertiary Lymphoid Structures
5:00–7:00 PM
Macdonald AB
Miriam Merad, Mount Sinai School of Medicine
Molecular and Spatial Correlates of Response to PD-1 Blockade in Human Tumors
Molecular and Spatial Correlates of Response to PD-1 Blockade in Human Tumors
Haydn Kissick, Emory University
A Stem-Like CD4 T Cell Controls Immunity to Cancer
A Stem-Like CD4 T Cell Controls Immunity to Cancer
Gabriel A. Rabinovich, Instituto de Biologia y Medicina Experimental
Galectins: Emerging Glyco-Checkpoints in the Tumor Microenvironment
Galectins: Emerging Glyco-Checkpoints in the Tumor Microenvironment
Teresa Dinter, MIT
Short Talk: The Signal Strength of Signal 2 and 3 During T Cell Priming Affect the Functional Fate of an Anti-tumor T Cell Response
Short Talk: The Signal Strength of Signal 2 and 3 During T Cell Priming Affect the Functional Fate of an Anti-tumor T Cell Response
Anna Juncker-Jensen, NeoGenomics
Short Talk: Spatial Relationship of Tertiary Lymphoid Structures and Neutrophils in Bladder Cancer and Prognostic Potential for PD-L1 Immunotherapy
Short Talk: Spatial Relationship of Tertiary Lymphoid Structures and Neutrophils in Bladder Cancer and Prognostic Potential for PD-L1 Immunotherapy
Jyh Liang Hor, National Institutes of Health
Short Talk: PD-1/cDC1 Axis in the Tumor Draining Lymph Node Regulates Stem-like CD8+ T Cell Differentiation
Short Talk: PD-1/cDC1 Axis in the Tumor Draining Lymph Node Regulates Stem-like CD8+ T Cell Differentiation
Social Hour with Lite Bites
7:00–8:00 PM
MacDonald CDEF
Poster Session 1
7:30–10:00 PM
MacDonald CDEF
Tuesday, March 19, 2024
Ruozhen Hu, Genentech
Anti-TIGIT Antibody Tiragolumab Leverages Myeloid Cells and Regulatory T Cells to Improve PD-L1 Checkpoint Blockade
Anti-TIGIT Antibody Tiragolumab Leverages Myeloid Cells and Regulatory T Cells to Improve PD-L1 Checkpoint Blockade
Kelsey E. Sivick Gauthier †, Arcus Biosciences, Inc.
Fc-silent anti-TIGIT Antibodies Offer Best-in-class Potential by Potentiating Robust CD8+ T Cell Mediated Anti-tumor Immunity Without Peripheral Regulatory T Cell Depletion
Fc-silent anti-TIGIT Antibodies Offer Best-in-class Potential by Potentiating Robust CD8+ T Cell Mediated Anti-tumor Immunity Without Peripheral Regulatory T Cell Depletion
Zoya Alteber, Compugen Ltd.
PVRIG is Uniquely Expressed in Tumor Dendritic Cell-rich Niches on Stem-like Memory T Cells and its Blockade May Induce Immune Infiltration and Activation in Non-inflamed Tumors
PVRIG is Uniquely Expressed in Tumor Dendritic Cell-rich Niches on Stem-like Memory T Cells and its Blockade May Induce Immune Infiltration and Activation in Non-inflamed Tumors
Thierry Guillaudeux, Kineta, Inc
VISTA-101 – An Ongoing Phase 1/2 Clinical Trial of KVA12123 Targeting VISTA, Alone and in Combination with Pembrolizumab in Advanced Solid Tumors
VISTA-101 – An Ongoing Phase 1/2 Clinical Trial of KVA12123 Targeting VISTA, Alone and in Combination with Pembrolizumab in Advanced Solid Tumors
Edward van der Horst, Sensei Biotherapeutics
VISTA Checkpoint Targeting by SNS-101, a pH-selective Antibody with Enhanced Safety and Pharmacokinetic Profiles, Alters the Tumor Microenvironment and Overcomes Immune Checkpoint Inhibitor Resistance
VISTA Checkpoint Targeting by SNS-101, a pH-selective Antibody with Enhanced Safety and Pharmacokinetic Profiles, Alters the Tumor Microenvironment and Overcomes Immune Checkpoint Inhibitor Resistance
Breakfast
7:00–8:00 AM
MacDonald CDEF
Novel Insights into T Cell Biology
8:00–11:00 AM
Macdonald AB
Andrea Schietinger, Memorial Sloan Kettering Cancer Center
Talk Title to be Announced
Talk Title to be Announced
Laura Codari Deak, Roche Innovation Center Zurich
PD-1 + IL-2 to Drive Differentiation of Effector T Cells in Tumor
PD-1 + IL-2 to Drive Differentiation of Effector T Cells in Tumor
colli Agudo, Dana-Farber Cancer Institute
Uncovering Hidden Drivers of Immune Evasion: Stemness and Cell Cycle
Uncovering Hidden Drivers of Immune Evasion: Stemness and Cell Cycle
Marcus Bosenberg, Yale University
Short Talk: Epigenetically Poised IL-7R+ CD8+ T Cells are Critical for Anti-melanoma Memory
Short Talk: Epigenetically Poised IL-7R+ CD8+ T Cells are Critical for Anti-melanoma Memory
Assaf Menachem, Compugen
Short Talk: Unleashing Natural IL-18 Activity Using an Anti-IL-18BP Blocker Antibody Induces Potent Immune Stimulation and Anti-tumor Effects
Short Talk: Unleashing Natural IL-18 Activity Using an Anti-IL-18BP Blocker Antibody Induces Potent Immune Stimulation and Anti-tumor Effects
Judit Díaz Gómez, Vall d'Hebron Institute of Oncology
Short Talk: Unravelling Tumor-intrinsic Resistance Mechanisms to T-cell Mediated Cytotoxicity in Pancreatic Cancer
Short Talk: Unravelling Tumor-intrinsic Resistance Mechanisms to T-cell Mediated Cytotoxicity in Pancreatic Cancer
Jacqueline Yee, University of California, San Francisco
Short Talk: CD40 Agonist Systemically Drives the Expansion of Tumor-Specific CD8 T Cells into a PD1+ KLRG1+ Effector State
Short Talk: CD40 Agonist Systemically Drives the Expansion of Tumor-Specific CD8 T Cells into a PD1+ KLRG1+ Effector State
Coffee Break
9:00–9:20 AM
Macdonald Foyer
On Own for Lunch
11:00–5:00 PM
Poster Setup
11:00–1:00 PM
MacDonald CDEF
Poster Viewing
1:00–10:00 PM
MacDonald CDEF
Career Roundtable
1:00–2:00 PM
Macdonald AB
Alena Gros, Vall d'Hebron Institute of Oncology
Group Leader of VHIO´s Tumor Immunology and Immunotherapy Group
Group Leader of VHIO´s Tumor Immunology and Immunotherapy Group
Andrea Cercek, Memorial Sloan Kettering Cancer Center
Associate Attending Physician
Associate Attending Physician
Edward van der Horst, Sensei Biotherapeutics
Chief Scientific Officer
Chief Scientific Officer
jed Gameiro, National Cancer Institute
Staff Scientist and Head of the Molecular Immunology Group of the Center for Immuno-Oncology, NCI
Staff Scientist and Head of the Molecular Immunology Group of the Center for Immuno-Oncology, NCI
Coffee Available
4:30–5:00 PM
Macdonald Foyer
Understanding Spatial Temporal Interactions Guiding Response and Resistance in the Tumor and Lymph Nodes
5:00–7:00 PM
Macdonald AB
Ronald N. Germain, NIAID, National Institutes of Health
Gaining Insight into Tumor Immunity by Combining New Highly Multiplex 2D and 3D Imaging with Analytical Tools
Gaining Insight into Tumor Immunity by Combining New Highly Multiplex 2D and 3D Imaging with Analytical Tools
Garry P. Nolan, Stanford University
Immune Pathology from the Subcellular Scale on Up
Immune Pathology from the Subcellular Scale on Up
Brian D. Brown, Mount Sinai School of Medicine
Spatial CRISPR
Spatial CRISPR
Soki Kashima, Yale Cancer Center, Yale School of Medicine
Short Talk: Exploring Resistance Mechanisms to Immune Checkpoint Inhibitor-based Therapies through Single-cell Analysis of Renal Cell Carcinoma
Short Talk: Exploring Resistance Mechanisms to Immune Checkpoint Inhibitor-based Therapies through Single-cell Analysis of Renal Cell Carcinoma
Katie Campbell, University of California, Los Angeles
Short Talk: Mature Endothelial Vessels Facilitate Tumor-infiltration by Checkpoint Positive T Cells Following Ipilimumab in Anti-PD-1-resistant Tumors
Short Talk: Mature Endothelial Vessels Facilitate Tumor-infiltration by Checkpoint Positive T Cells Following Ipilimumab in Anti-PD-1-resistant Tumors
Social Hour with Lite Bites
7:00–8:00 PM
MacDonald CDEF
Poster Session 2
7:30–10:00 PM
MacDonald CDEF
Wednesday, March 20, 2024
Alexander Keller, EPFL
Catalytically Inactive cGAS Potentiates Antitumor Immunity
Catalytically Inactive cGAS Potentiates Antitumor Immunity
Klaus Heger, Genentech, Inc
The Exonuclease TREX1 Constitutes an Innate Immune Checkpoint Limiting cGAS/STING-Mediated Anti-tumor Immunity
The Exonuclease TREX1 Constitutes an Innate Immune Checkpoint Limiting cGAS/STING-Mediated Anti-tumor Immunity
Eric Collisson †, University of California San Francisco
Leukemia Inhibitory Factor Fosters Immune Evasion in KRAS-driven Pancreatic Ductal Adenocarcinoma
Leukemia Inhibitory Factor Fosters Immune Evasion in KRAS-driven Pancreatic Ductal Adenocarcinoma
Jordan J. Cardenas, Yale University
Modified IL-18 Combined with Anti-PD1 Elicits a CD4+ T Cell-mediated Antitumor Response in MHC Class I-deficient Models of Non-small Cell Lung Cancer
Modified IL-18 Combined with Anti-PD1 Elicits a CD4+ T Cell-mediated Antitumor Response in MHC Class I-deficient Models of Non-small Cell Lung Cancer
Joan Seoane, Vall d'Hebron Institute of Oncology; Vall d'Hebron University Hospital
C1q Impairs the Response to Immunotherapies in Glioblastoma
C1q Impairs the Response to Immunotherapies in Glioblastoma
Hideho Okada, University of California, San Francisco
Glioma-neuronal Circuit Remodeling Induces Regional Immunosuppression
Glioma-neuronal Circuit Remodeling Induces Regional Immunosuppression
Kok Haw Jonathan Lim, The Francis Crick Institute
The Dendritic Cell Receptor DNGR-1 Couples Dead Cell Sensing to Cancer Immunoediting
The Dendritic Cell Receptor DNGR-1 Couples Dead Cell Sensing to Cancer Immunoediting
Emanuel Salazar Cavazos, National Cancer Institute / National Institutes of Health
Stochasticity in Cancer Immunotherapy Maps with the Rarity of Critical Spark T Cells
Stochasticity in Cancer Immunotherapy Maps with the Rarity of Critical Spark T Cells
Breakfast
7:00–8:00 AM
MacDonald CDEF
Engineering T Cells to Overcome Immune Resistance
8:00–11:00 AM
Macdonald AB
Yvonne Y. Chen, University of California, Los Angeles
Engineering Next-Generation CAR-T Cells for Cancer Immunotherapy
Engineering Next-Generation CAR-T Cells for Cancer Immunotherapy
Avery D. Posey, University of Pennsylvania
Chimeric Antigen Receptor T-Cells and Carbohydrate-Based Cancer Targets
Chimeric Antigen Receptor T-Cells and Carbohydrate-Based Cancer Targets
Justin Eyquem, University of California, San Francisco
Synthetic Immunology and Genome Editing Tools to Advance T Cell Therapies
Synthetic Immunology and Genome Editing Tools to Advance T Cell Therapies
Yuta Asano, Fred Hutchinson Cancer Center
Short Talk: Delayed Tumor Regression Following TCR-T, Anti-PD-L1 and IFNγ Combination Therapy in a Patient with Checkpoint Blockade-refractory HLA-downregulated Merkel Cell Carcinoma
Short Talk: Delayed Tumor Regression Following TCR-T, Anti-PD-L1 and IFNγ Combination Therapy in a Patient with Checkpoint Blockade-refractory HLA-downregulated Merkel Cell Carcinoma
Ian A. Parish, Peter MacCallum Cancer Centre
Short Talk: Ikaros Family Transcription Factors Cooperatively Enforce T Cell Exhaustion and Restrain CAR T Cell Efficacy
Short Talk: Ikaros Family Transcription Factors Cooperatively Enforce T Cell Exhaustion and Restrain CAR T Cell Efficacy
Angela C. Boroughs, ArsenalBio
Short Talk: Mapping CAR and TCR T Cell Exhaustion through Combinatorial CRISPR Screens
Short Talk: Mapping CAR and TCR T Cell Exhaustion through Combinatorial CRISPR Screens
Carli Stewart, Mayo Clinic Graduate School of Biomedical Sciences
Short Talk: Uncovering a Novel Role for IL-4 in the Development of CART Cell Exhaustion
Short Talk: Uncovering a Novel Role for IL-4 in the Development of CART Cell Exhaustion
Coffee Break
9:00–9:20 AM
Macdonald Foyer
On Own for Lunch
11:00–5:00 PM
Poster Setup
11:00–1:00 PM
MacDonald CDEF
Poster Viewing
1:00–10:00 PM
MacDonald CDEF
Coffee Available
4:30–5:00 PM
Macdonald Foyer
Tumor Antigens and Cancer Vaccines
5:00–6:45 PM
Macdonald AB
Alena Gros, Vall d'Hebron Institute of Oncology
Neoantigen Targeting with Tumor Infiltrating Lymphocytes
Neoantigen Targeting with Tumor Infiltrating Lymphocytes
Thamizhanban Manoharan, National University of Singapore
Short Talk: Exploring the Potential use of Alternate Neoantigens for the Generation of Therapeutic Cancer Vaccines to Improve Efficacy of Immune Checkpoint Blockade
Short Talk: Exploring the Potential use of Alternate Neoantigens for the Generation of Therapeutic Cancer Vaccines to Improve Efficacy of Immune Checkpoint Blockade
Matthew Gubin, MD Anderson
Short Talk: Overlapping and Distinct Mechanisms of Effective Neoantigen Cancer Vaccines and Immune Checkpoint Therapy
Short Talk: Overlapping and Distinct Mechanisms of Effective Neoantigen Cancer Vaccines and Immune Checkpoint Therapy
Sangeeta Goswami, MD Anderson Cancer Center
Histone Lactylation(s) Orchestrate Epigenetic and Transcriptional Networks Driving CD8 T Function
Histone Lactylation(s) Orchestrate Epigenetic and Transcriptional Networks Driving CD8 T Function
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Macdonald AB
Social Hour with Lite Bites
7:00–8:00 PM
MacDonald CDEF
Poster Session 3
7:30–10:00 PM
MacDonald CDEF
Departure
12:00–11:59 PM
Subscribe for Updates